


AMENDMENTS TO THE CLAIMS

1. (Currently amended) ~~Compounds~~ A compound of the General Formula (I)



Formula (I)

wherein:

A represents 4-ethylphenyl-, 4-isopropylphenyl-, 4-*tert.*-butylphenyl-, 2-methylphenyl-, 3-methylphenyl-, 4-cyclopropylphenyl, 3-fluorophenyl-, 2-chlorophenyl-, 3-chlorophenyl-, 4-bromophenyl-, 2-trifluoromethylphenyl-, 3-trifluoromethylphenyl-, 4-(1-hydroxy-1-methyl-ethyl)-phenyl-, 3-chloro-4-methylphenyl-, 2-methoxy-4-methylphenyl-, 3,4-difluorophenyl-, 1,2,3,4-tetrahydroisoquinolin-7-yl, 2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl, 2-formyl-1,2,3,4-tetrahydroisoquinolin-7-yl, phenylethenyl-, 1-naphthyl-, 2-naphthyl-, 3-methyl-pyridin-2-yl, 5-methyl-pyridin-2-yl, 5-isopropyl-pyridin-2-yl, 6-dimethylaminopyridin-3-yl, 6-bromo-5-chloro-pyridin-3-yl or 8-quinolinyl-;

B represents a phenyl, a 6-membered heteroaryl or a nine- or ten-membered bicyclic heteroaryl group, which groups are unsubstituted or independently mono- or di-substituted with cyano, halogen, hydroxy, lower alkyl, hydroxy lower alkyl, amino lower alkyl, aminocarbonyl lower alkyl, sulfonylamino lower alkyl, lower alkenyl, lower alkoxy, trifluoromethyl, trifluoromethoxy, cycloalkyloxy, aryloxy, aralkyloxy, heterocyclyloxy, heterocyclyl lower alkyloxy, amino, aminocarbonyl or sulfonylamino; or a cyclohexyl, 3-piperidinyl or 4-piperidinyl group, which groups are unsubstituted or mono-substituted with hydroxy, lower alkyl, hydroxy lower alkyl, aminocarbonyl lower alkyl, sulfonylamino lower alkyl, amino, aminocarbonyl or sulfonylamino;

with the proviso that in case A represents 2-methylphenyl- or 4-bromophenyl the phenyl ring as represented by B is substituted;

R¹ represents lower alkyl, cycloalkyl, hydroxy lower alkyl or cyano lower alkyl;

R² represents lower alkyl, lower alkenyl, hydroxy lower alkyl, amino lower alkyl, sulfonylamino lower alkyl, cycloalkyl; an unsubstituted or mono- or disubstituted phenyl group substituted independently with cyano, halogen, hydroxy, lower alkyl, lower alkoxy, cycloalkyloxy, amino, amino lower alkyl, aminocarbonyl or sulfonylamino; an unsubstituted or mono- or di-substituted five- or six-membered heteroaryl group substituted independently with cyano, halogen, hydroxy, lower alkyl, lower alkoxy, cycloalkyloxy, amino, amino lower alkyl, aminocarbonyl or sulfonylamino; or an unsubstituted or mono- or di-substituted nine- or ten-membered bicyclic heteroaryl group substituted independently with cyano, halogen, hydroxy, lower alkyl, lower alkoxy, cycloalkyloxy, amino, amino lower alkyl, aminocarbonyl or sulfonylamino;

and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.

2. (Currently amended) ~~Compounds of formula (I)~~ The compound of claim 1 wherein:

A represents a 4-ethylphenyl group;

~~B, R¹ and R² have the meaning given in claim 1;~~

and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.

3. (Currently amended) ~~Compounds of formula (I)~~ The compound of claim 1

wherein:

A represents a 4-isopropylphenyl group;

~~B, R¹ and R² have the meaning given in claim 1;~~

and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.

4. (Currently amended) ~~Compounds of formula (I)~~ The compound of claim 1

wherein:

A represents a 4-tert.-butylphenyl group;

~~B, R¹ and R² have the meaning given in claim 1;~~

and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.

5. (Currently amended) ~~Compounds of formula (I)~~ The compound of claim 1

wherein:

A represents a 2-methylphenyl group; and

B has the meaning given in claim 1 with the proviso that the phenyl group is substituted;

~~R¹ and R² have the meaning given in claim 1;~~

and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.

6. (Currently amended) ~~Compounds of formula (I)~~ The compound of claim 1

wherein:

A represents a 3-methylphenyl group;

~~B, R¹ and R² have the meaning given in claim 1;~~

and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.

7. (Currently amended) ~~Compounds of formula (I)~~ The compound of claim 1

wherein:

A represents a 4-(1-hydroxy-1-methyl-ethyl)-phenyl group;

~~B, R¹ and R² have the meaning given in claim 1;~~

and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.

8. (Currently amended) ~~Compounds of formula (I)~~ The compound of claim 1

wherein:

A represents a 3-chloro-4-methylphenyl group;

~~B, R¹ and R² have the meaning given in claim 1;~~

and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.

9. (Currently amended) ~~Compounds of formula (I)~~ The compound of claim 1

wherein:

A represents a 2-formyl-1,2,3,4-tetrahydroisoquinolin-7-yl group;

~~B, R¹ and R² have the meaning given in claim 1;~~

and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.

10. (Currently amended) ~~Compounds of formula (I)~~ The compound of claim 1

wherein:

A represents a 2-naphthyl group;

~~B, R¹ and R² have the meaning given in claim 1;~~

and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.

11. (Currently amended) ~~Compounds of formula (I)~~ The compound of claim 1

wherein:

A represents a 3-methyl-pyridin-2-yl group;

~~B, R¹ and R² have the meaning given in claim 1;~~

and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.

12. (Currently amended) ~~Compounds of formula (I)~~ The compound of claim 1

wherein:

A represents a 5-isopropyl-pyridin-2-yl group;

~~B, R¹ and R² have the meaning given in claim 1;~~

and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.

13. (Currently amended) ~~Compounds of formula (I)~~ The compound of claim 1

wherein:

A represents a 6-dimethylamino-pyridin-3-yl group;

~~B, R¹ and R² have the meaning given in claim 1;~~

and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.

14. (Currently amended) A compound according to claim 1, selected from the group consisting of

2-[(4-tert-Butyl-benzenesulfonyl)-p-tolyl-amino]-N,N-diethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-(4-methoxy-phenyl)-amino]-N,N-diethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-(3-methoxy-phenyl)-amino]-N,N-diethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-m-tolyl-amino]-N,N-diethyl-acetamide;

2-[(6-Dimethylamino-pyridine-3-sulfonyl)-p-tolyl-amino]-N-ethyl-N-pyridin-2-ylmethyl-acetamide;

N-Benzyl-2-[(4-tert-butyl-benzenesulfonyl)-*p*-tolyl-amino]-*N*-ethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-*p*-tolyl-amino]-*N*-ethyl-*N*-pyridin-4-ylmethyl-acetamide;

N,N-Diethyl-2-[(2-methoxy-phenyl)-(toluene-2-sulfonyl)-amino]-acetamide;

N-Benzyl-*N*-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-acetamide;

N-Benzyl-*N*-ethyl-2-[(2-methoxy-phenyl)-(toluene-2-sulfonyl)-amino]-acetamide;

N-Benzyl-2-[(4-tert-butyl-benzenesulfonyl)-(2-methoxy-phenyl)-amino]-*N*-ethyl-acetamide;

N-Benzyl-*N*-ethyl-2-[(6-methoxy-pyridin-3-yl)-(naphthalene-2-sulfonyl)-amino]-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-*p*-tolyl-amino]-*N*-ethyl-*N*-(2-hydroxy-ethyl)-acetamide;

2-[(3-Chloro-4-methyl-benzenesulfonyl)-*p*-tolyl-amino]-*N,N*-diethyl-acetamide;

N-Benzyl-2-[(4-tert-butyl-benzenesulfonyl)-*p*-tolyl-amino]-*N*-(2-hydroxy-ethyl)-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-*p*-tolyl-amino]-*N*-(2-cyano-ethyl)-*N*-ethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-*p*-tolyl-amino]-*N*-ethyl-*N*-pyridin-2-ylmethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-*p*-tolyl-amino]-*N*-ethyl-*N*-pyridin-3-ylmethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-*p*-tolyl-amino]-*N*-ethyl-*N*-(6-methyl-pyridin-2-ylmethyl)-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-p-tolyl-amino]-*N*-ethyl-*N*-thiazol-2-ylmethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-(3-dimethylamino-phenyl)-amino]-*N,N*-diethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-(3-dimethylamino-phenyl)-amino]-*N*-ethyl-*N*-pyridin-2-ylmethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-(3-dimethylamino-phenyl)-amino]-*N*-ethyl-*N*-(6-methyl-pyridin-2-ylmethyl)-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-p-tolyl-amino]-*N*-ethyl-*N*-(3-hydroxy-benzyl)-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-(1H-indazol-6-yl)-amino]-*N*-ethyl-*N*-(6-methyl-pyridin-2-ylmethyl)-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-(1H-indazol-6-yl)-amino]-*N*-ethyl-*N*-pyridin-2-ylmethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-p-tolyl-amino]-*N*-(2-hydroxy-ethyl)-*N*-pyridin-2-ylmethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-(3-dimethylamino-phenyl)-amino]-*N*-(2-hydroxy-ethyl)-*N*-pyridin-2-ylmethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-p-tolyl-amino]-*N*-cyclopropyl-*N*-(3-methoxy-benzyl)-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-(3-dimethylamino-phenyl)-amino]-*N*-cyclopropyl-*N*-(3-methoxy-benzyl)-acetamide;

N-Ethyl-2-[(2-methoxy-phenyl)-(toluene-2-sulfonyl)-amino]-*N*-thiazol-2-ylmethyl-acetamide;

N-Benzyl-*N*-(2-hydroxy-ethyl)-2-[(2-methoxy-phenyl)-(toluene-2-sulfonyl)-amino]-acetamide;

N-Ethyl-2-[(2-methoxy-phenyl)-(toluene-2-sulfonyl)-amino]-*N*-pyridin-2-ylmethyl-acetamide;

N-Ethyl-*N*-(3-hydroxy-benzyl)-2-[(2-methoxy-phenyl)-(toluene-2-sulfonyl)-amino]-acetamide;

N-Ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-*N*-(6-methyl-pyridin-2-ylmethyl)-acetamide;

N-Benzyl-*N*-(2-hydroxy-ethyl)-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-acetamide;

N-Ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-*N*-pyridin-3-ylmethyl-acetamide;

N-Ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-*N*-pyridin-2-ylmethyl-acetamide;

N-Ethyl-2-[(2-methoxy-phenyl)-(3-methyl-pyridine-2-sulfonyl)-amino]-*N*-(6-methyl-pyridin-2-ylmethyl)-acetamide;

N-Benzyl-*N*-ethyl-2-[(2-methoxy-phenyl)-(3-methyl-pyridine-2-sulfonyl)-amino]-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-(6-methyl-pyridin-3-yl)-amino]-*N*-ethyl-*N*-pyridin-2-ylmethyl-acetamide;

N-Benzyl-2-[(4-tert-butyl-benzenesulfonyl)-(6-methyl-pyridin-3-yl)-amino]-*N*-ethyl-acetamide;

N-Ethyl-2-[(6-methoxy-pyridin-3-yl)-(3-methyl-pyridine-2-sulfonyl)-amino]-*N*-(6-methyl-pyridin-2-ylmethyl)-acetamide; and

N-Benzyl-*N*-ethyl-2-[(6-methoxy-pyridin-3-yl)-(3-methyl-pyridine-2-sulfonyl)-amino]-acetamide;

15. (Currently amended) ~~Pharmaceutical compositions for the treatment of disorders which are associated with the role of orexin~~ A pharmaceutical composition

comprising one or more compounds of ~~any one of claims 1 to 14~~ claim 1, or a pharmaceutically acceptable salt thereof, as active ingredients, and ~~usual a pharmaceutically acceptable carrier materials and adjuvants~~ or adjuvant, or both.

16. (Cancelled).

17. (Cancelled).

18. (Cancelled).

19. (Original) A method of treating or preventing diseases or disorders where an antagonist of human orexin receptors is required, which comprises administering to a subject in need thereof an effective amount of a compound as claimed in any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof.

20. (Currently amended) A process for the manufacture of the pharmaceutical ~~compositions for the treatment of disorders mentioned in claim 15 or 16, containing one or more compounds as claimed in any one of claims 1 to 14, or a pharmaceutically acceptable salt or salts thereof, as active ingredients which process comprises~~ composition of claim 15, comprising mixing one or more active ingredient or ingredients with a pharmaceutically acceptable excipients and adjuvants in a manner known per se excipient or adjuvant, or both.

21. (Cancelled).

22. (Original) A compound as described as end-product in any one of examples 1 to 209.

23. (New) The pharmaceutical composition of claim 15 further comprising an additional pharmacologically active compound.

24. (New) The pharmaceutical composition of claim 23, wherein the additional pharmacologically active compound is selected from the group consisting of other orexin receptor antagonists, lipid lowering agents, anorectic agents, sleep inducing agents, antidepressants, other drugs beneficial for the prevention or treatment of diseases or disorders where an antagonist of human orexin receptors is required, eating disorders, sleep disorders, cardiovascular disorders, cancer, pain, depression, anxiety, schizophrenia, neurodegenerative disorders and hyperthermia syndromes.

25. (New) A method of treating a disorder which is associated with a role of orexins, comprising administering to a subject in need thereof an effective amount of a compound as claimed in claim 1.

26. (New) A method of treating eating disorders, sleep disorders, cardiovascular disorders, cancer, pain, depression, anxiety, schizophrenia, neurodegenerative disorders or hyperthermia syndromes, comprising administering to a subject in need thereof an effective amount of a compound as claimed in claim 1.